Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab and ESHAP in relapsed or refractory classic Hodgkin's lymphoma
NCT01195766Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Jul 2010
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ofatumumab in classical Hodgkin lymphoma (cHL), sponsored by GELTAMO. Primary endpoint: Overall Response Rate at 4 years. Started Jul 2010; status: completed.
02
Drugs
ofatumumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT01195766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01195766.